Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is China A Black Swan For Big Pharma? (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]

You may also be interested in...



GSK Carving Out Strategic Strengths In Emerging Markets: Euro-Biotech Partnering Summit

GSK VP Paul Bolno on market-specific opportunities in Asia.

Ascletis Gets Record Funding From China’s Hangzhou Development Zone For HIV/AIDs Drug Research

Hangzhou National Hi-Tech Industrial Development Zone awarded U.S.-China hybrid Ascletis a $1.6 million grant to fund research for HIV/AIDs drugs, the highest amount paid to date by a program aimed at wooing top Chinese national research talent back home.

PharmAsia News Favorite Stories From 2011

If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.

Related Content

UsernamePublicRestriction

Register

SC077769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel